After what many considered a “slow” year for IPOs, January has ushered in a string of biotechs filing to go public. But 2024 ...

Delve into the increasingly dynamic landscape of ALS treatment development with thirteen companies advancing candidates in ...

Selective stock-picking and conviction drove HB Biotech’s strong 2024 performance. Read our insights on navigating today’s ...

AI, biotech and affordable clean energy will be the focus of an EU drive to make the bloc globally competitive and ensure it ...

For 25 years, it was Joe Panetta’s job to tell the story of San Diego’s biotechnology community to the world. And the job ...

The China-based cancer drug developer’s offering will fund testing of medicines for several blood malignancies — one of which is part of an alliance with Takeda.

Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox.

Unnatural Products, a Santa Cruz-based biotech company founded by UC Santa Cruz alumni Cameron Pye and Joshua Schwochert ...

China has become a key piece of Foresite Capital’s investment and company formation strategy. During the J.P. Morgan Healthcare Conference, Managing Director Michael Rome shared his thoughts on why ...

The Trump administration has a historic opportunity to secure the United States’ position as the 21st-century biopower.

Biotech and pharma dealmaking is off to a good start in 2025. Meanwhile, digital health fundraising defined by “David and ...